Related Experiment Videos

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines

S Ostrand-Rosenberg¹, B A Pulaski, T D Armstrong

¹Department of Biological Sciences, University of Maryland, Baltimore 21250, USA. srosenbe@umbc.edu

Advances in Experimental Medicine and Biology

|February 23, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Mouse SaI sarcoma tumor model.

Current protocols in immunology·2008

Mouse 4T1 breast tumor model.

Current protocols in immunology·2008

H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens.

Journal of immunology (Baltimore, Md. : 1950)·2001

MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.

Traffic (Copenhagen, Denmark)·2001

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Journal of immunology (Baltimore, Md. : 1950)·2000

Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.

Journal of immunology (Baltimore, Md. : 1950)·2000

See all related articles